Evidence map›Paper›PMID 19606934›Full record

ArticleHuman gene therapy2009

Developing cell therapy techniques for respiratory disease: intratracheal delivery of genetically engineered stem cells in a murine model of airway injury.

Anne-Laure Leblond, Patrice Naud, Virginie Forest, Clothilde Gourden, Christine Sagan, Bénédicte Romefort, Eva Mathieu, Bruno Delorme, Christine Collin, Jean-Christophe Pagès and 3 more

Open access · greenAbstract read
In one paragraph

Article in Human gene therapy, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 1 pooled it
4.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 1 synthesis or guideline pooled it, 64 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Strategies for Modifying Adenoviral Vectors for Gene Therapy.International journal of molecular sciences · 2024
    Review
  4. Viral airway injury promotes cell engraftment in an in vitro model of cystic fibrosis cell therapy.American journal of physiology. Lung cellular and molecular physiology · 2024
    Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Assessing Human Airway Epithelial Progenitor Cells for Cystic Fibrosis Cell Therapy.American journal of respiratory cell and molecular biology · 2020
    Article
  10. Bioengineering of Pulmonary Epithelium With Preservation of the Vascular Niche.Frontiers in bioengineering and biotechnology · 2020
    Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Efficient intratracheal delivery of airway epithelial cells in mice and pigs.American journal of physiology. Lung cellular and molecular physiology · 2015
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Anne-Laure LeblondINSERM, UMR915, Institut du Thorax, Nantes, France.
Patrice Naud
Virginie Forest
Clothilde Gourden
Christine Sagan
Bénédicte Romefort
Eva Mathieu
Bruno Delorme
Christine Collin
Jean-Christophe Pagès
Luc Sensebé
Bruno Pitard
Patricia Lemarchand
Centre National de la Recherche Scientifique · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Interest has increased in the use of exogenous stem cells to optimize lung repair and serve as carriers of a therapeutic gene for genetic airway diseases such as cystic fibrosis. We investigated the survival and engraftment of exogenous stem cells after intratracheal injection, in a murine model of acute epithelial airway injury already used in gene therapy experiments on cystic fibrosis. Embryonic stem cells and mesenchymal stem cells were intratracheally injected 24 hr after 2% polidocanol administration, when epithelial airway injury was maximal. Stem cells were transfected with reporter genes immediately before administration. Reporter gene expression was analyzed in trachea-lungs and bronchoalveolar lavage, using nonfluorescence, quantitative, and sensitive methods. Enzyme-linked immunosorbent assay quantitative results showed that 0.4 to 5.5% of stem cells survived in the injured airway. Importantly, no stem cells survived in healthy airway or in the epithelial lining fluid. Using 5-bromo-4-chloro-3-indolyl-beta-d-galactopyranoside staining, transduced mesenchymal stem cells were detected in injured trachea and bronchi lumen. When the epithelium was spontaneously regenerated, the in vivo amount of engrafted mesenchymal stem cells from cell lines decreased dramatically. No stem cells from primary culture were located within the lungs at 7 days. This study demonstrated the feasibility of intratracheal cell delivery for airway diseases with acute epithelial injury.

Indexed as

Analysis of VarianceAnimalsbeta-GalactosidaseBronchoalveolar LavageCell- and Tissue-Based TherapyDNA PrimersEmbryonic Stem CellsEnzyme-Linked Immunosorbent AssayGalactosidesGenetic EngineeringGenetic VectorsIndolesMaleMesenchymal Stem Cell TransplantationMiceRespiratory Tract Diseases5-bromo-4-chloro-3-indolyl beta-galactosidebeta-GalactosidaseDNA PrimersGalactosidesIndoles

Identifiers

PMID19606934
PMCPMC3233538
OpenAlexW2104198623

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.